NEW YORK, NY--(Marketwired - July 26, 2016) - The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Insmed Incorporated ("Insmed" or the "Company") (NASDAQ: INSM) between March 18, 2013 and June 8, 2016.
You are hereby notified that a securities class action has commenced in the USDC for the District of New Jersey. If you purchased or otherwise acquired Insmed securities between March 18, 2013 and June 8, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/insmed-incorporated.
The complaint alleges that, throughout the Class Period, defendants issued false and misleading statements to investors and/or failed to disclose that: (1) the data supporting Insmed's European marketing authorization application ("MAA") for lead product candidate ARIKAYCE was not likely to be approved by the European Medicines Agency ("EMA") for the treatment of NTM lung disease, and (2) therefore ARIKAYCE'S approval by the EMA and subsequent commercialization in Europe were less likely and/or imminent than Insmed led investors to believe.
On June 8, 2016, Insmed announced it had withdrawn its MAA for ARIKAYCE from the EMA, revealing that the Committee for Medicinal Products for Human Use indicated that the phase 2 study did not provide a sufficient amount of evidence to support an approval.
If you suffered a loss in Insmed you have until September 13, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/insmed-incorporated.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm's attorneys have extensive experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.